Human leucocyte interferon-α in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-α: A randomized controlled trial

Journal of Viral Hepatitis

Volumn 4, Issue 3, 1997, Pages 209-214

  Gaeta, G B ^a,d   Di Virgilio, D ^b   Russo, G ^a   Stornaiuolo, G ^a   Nicolella, U ^b   Colella, F ^b   Grimaldi, M ^c   Pasquale, G ^a   Giusti, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Vannini Hospital   (Italy)

^c Alfa Wassermann SpA   (Italy)

^d c/o Osp Gesù e Maria ^*  (Italy)

Author keywords

Chronic hepatitis C; Human leucocyte interferon ; Lymphoblastoid interferon ; Non responder patients; Recombinant interferon

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-ALPHA; LEUKOCYTES; MALE; MIDDLE AGED;

EID: 0031134620     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1997.00146.x     Document Type: Article

References (27)

1. Davis GL. Recombinant alfa-interferon treatment of nonA, nonB (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990; 11: 572-572.
2. Saracco G, Rizzetto M. The long-term efficacy of interferon alfa in chronic hepatitis C patients: a critical review. J Gastroenterol Hepatol 1995; 10: 668-673.
3. Bonkovsily HL, Clifford BD, Smith LJ, Allan L, Banner B. High dose interferon α2b for re-treatment of non responders or relapsing patients with chronic hepatitis C. A controlled randomized trial. Dig Dis Sci 1996; 41: 149-154.
4. Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon alfa resistant for interferon alfa chronic hepatitis C. Gastroenterology 1994;107:812-817.
5. Beloqui O, Prieto J, Suarez M et al. N-acetyl cysteine enhances the response to interferon in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279-282.
6. Andreone P, Gramenzi A, Cursaro C et al. A randomized controlled trial of IFNα + Ketoprofen or IFNα + Ribavirin in HCV chronic active hepatitis (CAH) non-responder to IFNα alone. Hepatology 1995; 22: 2 (abstr 52).
7. Viscomi P, Grimaldi M, Palazzini E, Silvestri S. Human leukocyte interferon alfa: structure, pharmacology and therapeutic application. Med Res Rev 1995; 15: 445-478.
8. Interferon Alfa-N3. Physicians Genrix. The official drug reference of FDA prescribing information and therapeutic, Equivalents, II, 1145.
9. Von Wussow P, Pralle H, Hochkeppel HK et al. Effective natural interferon-α therapy in recombinant Interferon α resistant patients with hairy cell leukemia. Blood 1991; 78: 38-43.
10. Casato M, Laganà B, Antonelli G, Dianzani F, Bonomo L. Long-term results of therapy with interferon α for type II essential mixed cryoglobulinemia. Blood 1991; 78: 3142-3147.
11. Von Wussow P, Jakschies D, Freund M et al. Treatment of anti-recombinant interferon alpha2 antibody positive CML patients with natural interferon alfa. Br J Haematol 1991; 78: 210-216.
12. Merup M, Tornebohm-Roche E, Engman K, Paul C. Human leucocyte interferon α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon α2a. Eur J Cancer 1994; 30a: 1729-1730.
13. Milella M, Santantonio T, Monno L et al. Human leucocyte alfa interferon in the treatment of chronic hepatitis C. Medit J Infect Parasit Dis 1993; VIII: 227-231.
14. Desmet VS, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, Grading and Staging. Hepatology 1994; 19: 1553-1560.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. Pontisso P, Ruvoletto MG, Nicoletti M et al. Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. J Viral Hep 1995; 2: 33-38.
17. Marcellin P, Pouteau M, Boyer N, Castlenau C, Erlinger S, Benhamou. Retreatment with recombinant interferon α in patients with chronic hepatitis C. J Infect Dis 1993; 167: 780-788.
18. Toyoda H, Nakano S, Takada I et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89: 1453-1457.
19. Bresci G, Parisi G, Banti S, Capria A. Retreatment of interferon resistant patients with chronic hepatitis C with interferon α. J Viral Hep 1995; 2: 155-158.
20. Shindo M, Di Bisceglie M, Hoofnagle JM. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15: 1013-1016.
21. Saracco G, Rosina F, Abate ML et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α2b. Hepatology 1993; 18: 1300-1305.
22. Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 1342-1346.
23. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa 2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
24. Nishiguchi S, Kuroki T. Nakatomi S et al. Randomised trial of effects of interferon α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
25. Mazzella G, Accogli E, Sottili S et al. Alfa interferon treatment may prevent hepatocellular carcinoma in HCV related liver cirrhosis. J Hepatol 1996; 24: 141-147.
26. Shindo M, Arai K, Sokama Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long term response to interferon α therapy. Ann Intern Med 1995; 122: 586-591.
27. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alfa 2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.